文献速递淋巴瘤

MRD驱动的维奈克拉-R2治疗套细胞淋巴瘤:北欧淋巴瘤组MCL7 VALERIA试验

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
PubMed 文献 · Blood Adv · 2024-01-01

这项多中心1b/2期试验评估MRD驱动的维奈克拉、来那度胺和利妥昔单抗(维奈克拉-R2)在复发/难治套细胞淋巴瘤中的安全性和疗效,并探索分子缓解后停药可行性。共纳入59例患者,中位年龄73岁,6个月总缓解率为63%,中位无进展生存期21个月,中位总生存期31个月。28例(48%)在分子缓解后停药,25例在中位17.4个月后仍MRD阴性。

要点

  • 推荐2期剂量为来那度胺20 mg每日第1-21天、维奈克拉600 mg每日、利妥昔单抗375 mg/m2每周4次后每8周。
  • 6个月总缓解率63%(29例完全缓解,8例部分缓解),既往BTK抑制剂失败患者为40%。
  • TP53突变与较差的无进展生存期相关(P < .01)。

核心结论

  • MRD驱动的维奈克拉-R2在复发/难治套细胞淋巴瘤中可行、可耐受且显示疗效,BTK抑制剂失败后亦显示疗效。

研究设计与样本

  • 多中心1b/2期试验,纳入59例复发/难治套细胞淋巴瘤患者,中位年龄73岁,主要终点为6个月总缓解率。

主要发现

  • 6个月总缓解率为63%(29例完全缓解,8例部分缓解),既往BTK抑制剂失败患者为40%(4例完全缓解,2例部分缓解)。
  • 中位无进展生存期为21个月,中位总生存期为31个月。
  • TP53突变与较差的无进展生存期相关(P < .01)。
  • 28例(48%)在分子缓解后停药,25例在中位17.4个月后仍MRD阴性。
  • 52/59(88%)患者发生G3-4中性粒细胞减少,21/59(36%)患者发生G3-4血小板减少。

关键数值与推荐

  • 推荐2期剂量:来那度胺20 mg每日,第1-21天;维奈克拉600 mg每日(递增后);利妥昔单抗375 mg/m2每周4周,之后每8周。
  • 每3个月通过RQ-PCR进行MRD监测;血液MRD阴性后继续治疗3个月,再次确认MRD阴性后停药。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite improvements in treatment of mantle cell lymphoma (MCL), most patients eventually relapse. In this multicenter phase 1b/2 trial, we evaluated safety and efficacy of minimal residual disease (MRD)-driven venetoclax, lenalidomide, and rituximab (venetoclax-R2) in relapsed/refractory (R/R) MCL and explored the feasibility of stopping treatment in molecular remission. The primary end point was overall response rate (ORR) at 6 months. After dose escalation, the recommended phase 2 dose was lenalidomide 20 mg daily, days 1 to 21; venetoclax 600 mg daily after ramp-up; and rituximab 375 mg/m2 weekly for 4 weeks, then every 8 weeks. MRD monitoring by RQ-PCR was performed every 3 months. When MRD-negativity in the blood was reached, treatment was continued for another 3 months; if MRD-negativity was then confirmed, treatment was stopped. In total, 59 patients were enrolled, with a median age of 73 years. At 6 months, the ORR was 63% (29 complete remission [CR], 8 partial remission [PR]), and 40% (4 CR, 2 PR) for patients previously failing a Bruton tyrosine kinase (BTK) inhibitor. Median progression-free survival (PFS) was 21 months, with median overall survival of 31 months. TP53 mutation was associated with inferior PFS (P < .01). Overall, 28 patients (48%) discontinued treatment in molecular remission, and 25 remain MRD negative after a median of 17.4 months. Hematological toxicity was frequent, with 52 of 59 (88%) patients with G3-4 neutropenia and 21 of 59 (36%) patients with G3-4 thrombocytopenia. To conclude, MRD-driven venetoclax-R2 is feasible and tolerable and shows efficacy in R/R MCL, also after BTK inhibitor failure. This trial was registered at www.ClinicalTrials.gov as #NCT03505944.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jerkeman M, Kolstad A, Hutchings M, et al. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood Adv. 2024. PMID: 38113470. doi:10.1182/bloodadvances.2023011920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。